Teamwork Financial Advisors LLC Makes New Investment in Natera, Inc. $NTRA

Key Points

• Teamwork Financial Advisors LLC bought 10,815 Natera shares worth approximately $2.94 million in the second quarter. Institutional investors and hedge funds collectively own 99.90% of NTRA.
• Natera reported second-quarter revenue of $752.75 million, up 37.7% year over year and above expectations, while its $0.47 per-share loss was slightly better than forecasts. The company remains unprofitable but narrowed its loss from the prior-year quarter.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $299.65. However, NTRA’s elevated valuation and recent insider selling could increase the risk of profit-taking.

Teamwork Financial Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,815 shares of the medical research company's stock, valued at approximately $2,936,000.

A number of other institutional investors have also modified their holdings of NTRA. FNY Investment Advisers LLC purchased a new stake in shares of Natera in the 2nd quarter valued at $59,000. Elevation Wealth Partners LLC acquired a new position in Natera during the 2nd quarter worth about $30,000. PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in Natera by 9.8% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 13,770 shares of the medical research company's stock valued at $3,738,000 after acquiring an additional 1,230 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Natera by 314.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 250,869 shares of the medical research company's stock valued at $68,098,000 after acquiring an additional 190,334 shares during the period. Finally, GAMMA Investing LLC grew its position in Natera by 17.3% in the 2nd quarter. GAMMA Investing LLC now owns 1,225 shares of the medical research company's stock valued at $333,000 after acquiring an additional 181 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wolfe Research initiated coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They issued a "neutral" rating and a $245.00 price objective for the company. Morgan Stanley upped their target price on shares of Natera from $250.00 to $310.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Robert W. Baird set a $348.00 target price on shares of Natera in a report on Friday. Finally, Evercore reiterated an "outperform" rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $299.65.

Natera Price Performance

NTRA stock opened at $322.10 on Friday. The business's 50-day moving average is $254.03 and its two-hundred day moving average is $223.79. The firm has a market capitalization of $46.13 billion, a P/E ratio of -236.84 and a beta of 1.51. Natera, Inc. has a 1 year low of $149.38 and a 1 year high of $323.01.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.82% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the company posted ($0.74) earnings per share. The business's revenue for the quarter was up 37.7% on a year-over-year basis. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Insider Activity at Natera

In other news, Director Gail Boxer Marcus sold 11,000 shares of the firm's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares of the company's stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 181,045 shares of company stock worth $41,330,968 over the last ninety days. 5.05% of the stock is currently owned by insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source